Avanir Deal Partly Plugs Otsuka’s Abilify Gap
This article was originally published in PharmAsia News
Executive Summary
While some eyebrows are being raised over the sum Otsuka Pharmaceutical is proposing to shell out for a small U.S. CNS company with only one niche marketed product, the pipeline the deal will bring is being viewed positively by some analysts.
You may also be interested in...
Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy
Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.
US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.
Otsuka/Lundbeck Closer To Adding Alzheimer’s Agitation To Rexulti Label
With no currently approved treatment for agitation in Alzheimer’s disease, analysts see a solid revenue opportunity for Rexulti. The companies plan to file a supplemental NDA later this year.